Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $37,555.38 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 918 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. This represents a 0.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total transaction of $12,661.80.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $36.71 on Tuesday. The firm has a market cap of $2.19 billion, a PE ratio of -10.86 and a beta of 2.15. The firm’s fifty day moving average is $46.54 and its 200-day moving average is $45.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.75) earnings per share. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently bought and sold shares of TWST. First Light Asset Management LLC bought a new position in Twist Bioscience during the fourth quarter worth $56,984,000. Thrivent Financial for Lutherans bought a new position in Twist Bioscience during the third quarter worth $43,992,000. Marshall Wace LLP raised its stake in Twist Bioscience by 15,927.8% during the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock worth $39,319,000 after buying an additional 840,828 shares during the last quarter. State Street Corp raised its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have weighed in on TWST shares. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.